ArticleEuropean journal of neurology2021
Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
Article in European journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies.PloS one · 2024Pooled it
- Epstein-Barr virus infection and vitamin D deficiency are both "causal" for multiple sclerosis (MS) - could the common denominator be their effects on hepcidin levels?Metabolic brain disease · 2025Review
- Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.Journal of neurology · 2025Article
- Validation of the Patient-Determined Disease Steps in ambulatory older adults with multiple sclerosis.Multiple sclerosis and related disorders · 2025Article
- Real-world brain volumetry in multiple sclerosis: importance of methodological consistency and clinical relevance of gray matter atrophy.Frontiers in neurology · 2025Article
- MiRNA-based therapeutic potential in multiple sclerosis.Frontiers in immunology · 2024Review
- Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment.Neurology and therapy · 2023Review
- Diagnosis and treatment of progressive multiple sclerosis: A position paper.European journal of neurology · 2023Review
- Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis.BMC neurology · 2022Article
- Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort.CNS neuroscience & therapeutics · 2022Article
- Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.Annals of neurology · 2022Observational
- Longitudinal changes of deep gray matter shape in multiple sclerosis.NeuroImage. Clinical · 2022Article
- Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.European journal of neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIn an era of individualized multiple sclerosis (MS) patient management, biomarkers for accurate prediction of future clinical outcomes are needed. We aimed to evaluate the potential of short-term magnetic resonance imaging (MRI) atrophy measures and serum neurofilament light chain (sNfL) as predictors of the dynamics of disability accumulation in relapse-onset MS.
methodsBrain gray and white matter, thalamic, striatal, pallidal and cervical spinal cord volumes, and lesion load were measured over three available time points (mean time span 2.24 ± 0.70 years) for 183 patients (140 relapsing-remitting [RRMS] and 43 secondary-progressive MS (SPMS); 123 female, age 46.4 ± 11.0 years; disease duration 15.7 ± 9.3 years), and their respective annual changes were calculated. Baseline sNfL was also measured at the third available time point for each patient. Subsequently, patients underwent annual clinical examinations over 5.4 ± 3.7 years including Expanded Disability Status Scale (EDSS) scoring, the nine-hole peg test and the timed 25-foot walk test.
resultsHigher annual spinal cord atrophy rates and lesion load increase predicted higher future EDSS score worsening over time in SPMS. Lower baseline thalamic volumes predicted higher walking speed worsening over time in RRMS. Lower baseline gray matter, as well as higher white matter and spinal cord atrophy rates, lesion load increase, baseline striatal volumes and baseline sNfL, predicted higher future hand dexterity worsening over time. All models showed reasonable to high prediction accuracy.
conclusionThis study demonstrates the capability of short-term MRI metrics to accurately predict future dynamics of disability progression in a real-world relapse-onset MS cohort. The present study represents a step towards the utilization of structural MRI measurements in patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.